As we enter the heart of second-quarter earnings reports, I can't help but point out that the majority we've covered over the past year have been better than expected. With so many companies reporting...... (read more)

As I noted nine weeks ago, cancer statistics are both staggering and disappointing. Although cancer deaths per 100,000 people have been on the downswing since 1991 thanks to access to more effective medications...... (read more)

What: Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a cancer therapeutics company, collapsed as much as 27% following the release of briefing documents today in anticipation of AVEO Pharmaceuticals...... (read more)

Last week we focused on five can't-miss earnings reports. This week, we're going to turn the tables back to the Food and Drug Administration and focus on a PDUFA decision and an FDA panel review slated...... (read more)

As I noted eight weeks ago, cancer statistics are both staggering and disappointing. Although cancer deaths per 100,000 people have been on the downswing since 1991 thanks to access to more effective...... (read more)

To say that William Leland Edwards of Palo Alto Investors invest heavily in healthcare stocks would be, well, a bit of an understatement.  The fund’s positions read like a pharmaceutical sales rep’...... (read more)

Few big biotech firms have been as successful recently as Celgene Corporation (NASDAQ:CELG). The maker of multiple myeloma home run drug Revlimid has seen its shares rocket higher by more than 38% over...... (read more)

Sequester or no sequester, the folks at the Food and Drug Administration look to be quite busy in 2013. Their schedules are full with plenty of important decisions that could greatly impact the fates...... (read more)

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) was in 24 hedge funds' portfolio at the end of December. ONXX investors should pay attention to a decrease in support from the world's most elite money managers...... (read more)